INNOVIVA, INC. Income (Loss) from Continuing Operations before Income Taxes, Domestic
INNOVIVA, INC. (INVA) reported Income (Loss) from Continuing Operations before Income Taxes, Domestic of $327.06 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Income Statement › Pre-tax Income
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic · last filed 2026-02-25
- INNOVIVA, INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2025 was $327.06M, a 775.38% increase from fiscal 2024.
- INNOVIVA, INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2024 was $37.36M, a 80.74% decline from fiscal 2023.
- INNOVIVA, INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2023 was $194.03M.
| Period end | Income (Loss) from Continuing Operations before Income Taxes, Domestic 12 month |
|---|---|
| 2025-12-31 | $327.06M 10-K · filed 2026-02-25 |
| 2024-12-31 | $37.36M 10-K · filed 2026-02-25 |
| 2023-12-31 | $194.03M 10-K · filed 2026-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |